| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SAN DIEGO—Pharmaceutical companies Ambit Biosciences and Cephalon recently an-nounced the signing of a screen­ing, discovery and development agreement that will see the companies tackle kinases, key molecules in many disease path­ways. Working on two undis­closed kinase targets, Ambit will discover and deliver lead compounds, which Cephalon will pursue for preclinical and clinical development as well as commercialization.
 
For their services, Ambit will receive $18 million upfront and potential milestone payments up to $232.5 million, as well as roy­alties on the sales of any products arising from the collaboration.
 
"Kinase inhibition as a mecha­nism for novel therapeutics is complex, extremely challenging from the aspect of finding a drug­gable chemotype and information-intensive," says Dr. Jeffrey Vaught, Cephalon executive VP of R&D. "We recognized very early that a strategic alliance with a kinome-centric organization would com­pliment and strengthen our inter­nal capabilities.
 
"After evaluating several tech­nologies, we felt that Ambit had several important attributes that included: world-class technology, a scientific and management team that understood and were com­mitted to drug discovery and an impressive track record of accom­plishment."
 
According to Dr. Shripad Bhagwat, Ambit senior VP of drug discovery, Ambit will also screen Cephalon's kinase-focused library using KinomeScan to select novel leads for multiple undisclosed kinase targets of interest to Ambit. The company retains rights to pur­sue these leads independently to discover kinase inhibitor drugs.
 
Ambit's screening platform, KinomeScan, works by directly and quantitatively measuring competitive binding of small mol­ecules to the ATP binding site of kinases. What sets the system apart, says Dr. Patrick Zarrinkar, Ambit senior director of technolo­gy development and alliance man­agement, is the ability to screen compounds on a massively paral­lel scale and under identical condi­tions. For example, 10,000 com­pounds can be screened against a panel of approximately 300 kinas­es, yielding 3,000,000 data points in months rather than years.
 
"We are entering an era in kinase research which is very sim­ilar to that with GPCRs where the breadth of potential interaction of the compound can dictate, not only efficacy, but potential unwanted off-target activities and toxicity," Vaught says. "KinomeScan offers real-time data back to the synthe­sizing chemist to inform his/her next synthesis."
 
One of the challenges in devel­oping kinase inhibitors is the ubiq­uity of the proteins throughout the human proteome—some estimates suggest as many as 500 different kinases—and their pivotal role as a primary point-of-entry for many biological pathways. At present, KinomeScan includes 300 kinases.
 
"The representation of kinase subfamilies in Ambit's panel is comparable to their representation in the human kinome as a whole," Zarrinkar says. "Ambit's panel will continue to grow, and we antici­pate that within two to three years the panel will contain the vast majority, if not all, human protein kinases."
 
From Vaught's perspective, how­ever, the distribution of kinases may actually be a blessing rather than a curse.
 
"While there is a lot of discus­sion around kinase inhibitor selec­tivity, I am much more interested in the potential ability to specifi­cally target multiple mechanisms, built into a single compound, which pharmacologically can be demonstrated to be complimen­tary, important to the pathology of disease and synergistic when combined," he says. "This would be and is impossible without a full panel of data from which to instruct and guide the synthesiz­ing chemist."
 
Cephalon, it would seem, is bet­ting on KinomeScan as a way to access this information.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue